BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 22722234)

  • 1. Reassessment of declines in pulmonary function ≥1 year after stereotactic body radiotherapy.
    Takeda A; Enomoto T; Sanuki N; Handa H; Aoki Y; Oku Y; Kunieda E
    Chest; 2013 Jan; 143(1):130-137. PubMed ID: 22722234
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Severe COPD is correlated with mild radiation pneumonitis following stereotactic body radiotherapy.
    Takeda A; Kunieda E; Ohashi T; Aoki Y; Oku Y; Enomoto T; Nomura K; Sugiura M
    Chest; 2012 Apr; 141(4):858-866. PubMed ID: 21885726
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pulmonary function testing after stereotactic body radiotherapy to the lung.
    Bishawi M; Kim B; Moore WH; Bilfinger TV
    Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):e107-10. PubMed ID: 21470798
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stereotactic Body Radiation Therapy for Non-Small Cell Lung Cancer Tumors Greater Than 5 cm: Safety and Efficacy.
    Woody NM; Stephans KL; Marwaha G; Djemil T; Videtic GM
    Int J Radiat Oncol Biol Phys; 2015 Jun; 92(2):325-31. PubMed ID: 25841625
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Is there a lower limit of pretreatment pulmonary function for safe and effective stereotactic body radiotherapy for early-stage non-small cell lung cancer?
    Guckenberger M; Kestin LL; Hope AJ; Belderbos J; Werner-Wasik M; Yan D; Sonke JJ; Bissonnette JP; Wilbert J; Xiao Y; Grills IS
    J Thorac Oncol; 2012 Mar; 7(3):542-51. PubMed ID: 22258475
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lack of a dose-effect relationship for pulmonary function changes after stereotactic body radiation therapy for early-stage non-small cell lung cancer.
    Guckenberger M; Klement RJ; Kestin LL; Hope AJ; Belderbos J; Werner-Wasik M; Yan D; Sonke JJ; Bissonnette JP; Xiao Y; Grills IS
    Int J Radiat Oncol Biol Phys; 2013 Mar; 85(4):1074-81. PubMed ID: 23154077
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Curative treatment of Stage I non-small-cell lung cancer in patients with severe COPD: stereotactic radiotherapy outcomes and systematic review.
    Palma D; Lagerwaard F; Rodrigues G; Haasbeek C; Senan S
    Int J Radiat Oncol Biol Phys; 2012 Mar; 82(3):1149-56. PubMed ID: 21640513
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stereotactic body radiotherapy for centrally located early-stage non-small cell lung cancer or lung metastases from the RSSearch(®) patient registry.
    Davis JN; Medbery C; Sharma S; Pablo J; Kimsey F; Perry D; Muacevic A; Mahadevan A
    Radiat Oncol; 2015 May; 10():113. PubMed ID: 25975848
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preliminary report of late recurrences, at 5 years or more, after stereotactic body radiation therapy for non-small cell lung cancer.
    Matsuo Y; Shibuya K; Nagata Y; Norihisa Y; Narabayashi M; Sakanaka K; Ueki N; Mizowaki T; Hiraoka M
    J Thorac Oncol; 2012 Feb; 7(2):453-6. PubMed ID: 22252562
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stereotactic body radiotherapy for second primary lung cancer and intra-parenchymal lung metastasis in patients previously treated with surgery: evaluation of indications and predictors of decreased respiratory function.
    Ishihara T; Yamada K; Harada A; Yukiue H; Tanahashi M; Niwa H; Matsui T; Yokomura K; Ejima Y; Sasaki R
    Acta Oncol; 2018 Sep; 57(9):1232-1239. PubMed ID: 29722594
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of tumor attachment to the pleura measured by a pretreatment CT image on outcome of stage I NSCLC treated with stereotactic body radiotherapy.
    Yamamoto T; Kadoya N; Shirata Y; Koto M; Sato K; Matsushita H; Sugawara T; Umezawa R; Kubozono M; Ishikawa Y; Kozumi M; Takahashi N; Ito K; Katagiri Y; Takeda K; Jingu K
    Radiat Oncol; 2015 Feb; 10():35. PubMed ID: 25886315
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stereotactic body radiation therapy versus conventional radiation therapy in patients with early stage non-small cell lung cancer: an updated retrospective study on local failure and survival rates.
    Jeppesen SS; Schytte T; Jensen HR; Brink C; Hansen O
    Acta Oncol; 2013 Oct; 52(7):1552-8. PubMed ID: 23902274
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Baseline pulmonary function as a predictor for survival and decline in pulmonary function over time in patients undergoing stereotactic body radiotherapy for the treatment of stage I non-small-cell lung cancer.
    Henderson M; McGarry R; Yiannoutsos C; Fakiris A; Hoopes D; Williams M; Timmerman R
    Int J Radiat Oncol Biol Phys; 2008 Oct; 72(2):404-9. PubMed ID: 18394819
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor volume change with stereotactic body radiotherapy (SBRT) for early-stage lung cancer: evaluating the potential for adaptive SBRT.
    Bhatt AD; El-Ghamry MN; Dunlap NE; Bhatt G; Harkenrider MM; Schuler JC; Zacarias A; Civelek AC; Pan J; Rai SN; Woo SY
    Am J Clin Oncol; 2015 Feb; 38(1):41-6. PubMed ID: 24513663
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stereotactic body radiotherapy for chronic obstructive pulmonary disease patients undergoing or eligible for long-term domiciliary oxygen therapy.
    Hara Y; Takeda A; Eriguchi T; Sanuki N; Aoki Y; Nishimura S; Enomoto T; Shinkai M; Kawana A; Kaneko T
    J Radiat Res; 2016 Jan; 57(1):62-7. PubMed ID: 26487713
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Changes in Pulmonary Function After Stereotactic Body Radiotherapy and After Surgery for Stage I and II Non-small Cell Lung Cancer, a Description of Two Cohorts.
    Alberts L; El Sharouni SY; Hofman FN; Van Putte BP; Tromp E; Van Vulpen M; Kastelijn EA; Schramel FM
    Anticancer Res; 2015 Dec; 35(12):6773-9. PubMed ID: 26637895
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Short-term outcomes and clinical efficacy of stereotactic body radiation therapy (SBRT) in treatment of adrenal gland metastases from lung cancer.
    Zhao X; Zhu X; Fei J; Ren H; Cao Y; Ju X; Yuan Z; Zhang H
    Radiat Oncol; 2018 Oct; 13(1):205. PubMed ID: 30348187
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stereotactic Ablative Body Radiotherapy (SABR) in Pulmonary Oligometastatic/Oligorecurrent Non-small Cell Lung Cancer Patients: A New Therapeutic Approach.
    Agolli L; Valeriani M; Nicosia L; Bracci S; De Sanctis V; Minniti G; Enrici RM; Osti MF
    Anticancer Res; 2015 Nov; 35(11):6239-45. PubMed ID: 26504057
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of the site of lobectomy and chronic obstructive pulmonary disease on pulmonary function: a follow-up analysis.
    Kushibe K; Kawaguchi T; Kimura M; Takahama M; Tojo T; Taniguchi S
    Interact Cardiovasc Thorac Surg; 2009 May; 8(5):529-33. PubMed ID: 19201779
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Survival and treatment of non-small cell lung cancer stage I-II treated surgically or with stereotactic body radiotherapy: patient and tumor-specific factors affect the prognosis.
    Mokhles S; Nuyttens JJ; Maat AP; Birim Ö; Aerts JG; Bogers AJ; Takkenberg JJ
    Ann Surg Oncol; 2015 Jan; 22(1):316-23. PubMed ID: 24962941
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.